#Corbevax

[medhahospital]

Government Covid-19 vaccination centres in Ghaziabad have been shut since December 26 when district authorities exhausted their stock of Covishield, Covaxin and Corbevax vaccine doses. No government vaccination centre was open in Ghaziabad on Friday, according to the CoWin portal, and the situation is likely to persist for another 10-12 days before new doses arrive, health officials said. “We are regularly following up with authorities for the vaccine stock and once we receive it, the vaccination process will restart as usual. As of now, government vaccination centres in Ghaziabad are not in operation due to non-availability of doses,” said GP Mathuria, nodal officer for Covid vaccination. After the district’s vaccine stock was exhausted, the health department sent a request to the divisional store in Meerut for 30,000 doses each of #Covishield, #Covaxin and #Corbevax, but the stock is yet to arrive. Chief medical officer Dr Bhavtosh Shankhdhar and nodal officer Dr Neeraj Agarwal did not respond to requests for comment. #medhahospitalandtraumacentre #medha #medhahospital (at Ghaziabad, India) https://www.instagram.com/p/CnUFTUNhVDO/?igshid=NGJjMDIxMWI=

[decentralvaccine]

WHO Authorizes Another Covid 19 Vaccine For Emergency Use

The World Health Organization (WHO) has approved another COVID-19 vaccine for emergency use listing (EUL): Corbevax, a recombinant protein–based vaccine developed by scientists at Texas Children's Hospital and Baylor College of Medicine.

During the EUL process, WHO advisory groups evaluated the vaccine to ensure that it meets the WHO's standards for protection and safety, with a goal of speeding the availability of products to people who need them. Corbevax is the 14th COVID vaccine to receive the WHO EUL.

[theprogressivesadist]

Year 4 of 2020 be like

[probablyasocialecologist]

CORBEVAX was developed by the co-directors of the Texas Children’s Hospital Center for Vaccine Development at Baylor College of Medicine, Drs. Maria Elena Bottazzi and Peter Hotez.

During the 2003 SARS outbreak, these researchers created a similar type of vaccine by inserting the genetic information for a portion of the SARS virus spike protein into yeast to produce large amounts of the protein. After isolating the virus spike protein from the yeast and adding an adjuvant, which helps trigger an immune response, the vaccine was ready for use.

The first SARS epidemic was short-lived, and there was little need for Bottazzi and Hotez’s vaccine – until the virus that causes COVID-19, SARS-CoV-2, emerged in 2019. So they dusted off their vaccine and updated the spike protein to match that of SARS-CoV-2, creating the CORBEVAX vaccine.

This vaccine can be produced at a much larger scale because appropriate manufacturing facilities are already available. Also key to global access is that CORBEVAX can be stored in a regular refrigerator. Therefore, it is possible to produce millions of doses rapidly and distribute them relatively easily. In comparison, producing mRNA vaccines is more expensive and complicated because they are based on newer technologies, rely on highly skilled workers and often require ultralow temperatures for storage and transport.

Another major difference is that the CORBEVAX vaccine was developed with global vaccine access in mind. The goal was to make a low-cost, easy-to-produce and -transport vaccine using a well-tested and safe method. Key to this, the researchers were not concerned with intellectual property or financial benefit. The vaccine was produced without significant public funding; the US$7 million needed for development was provided by philanthropists.

[the-fox-populi-says]

GUYS HOLY SHIT

PATENT FREE VACCINE JUST DROPPED

I can hardly believe it but it really seems legit??

Could it be???

[afragmentcastadrift]

New COVID vaccine from Texas could be a global game changer : Goats and Soda : NPR

[voidingintotheshout]

Sure, or instead of trying to get western countries to share the Pfizer and Moderna vaccines; countries could just have the just as effective and cheaper and easier to produce Patent-free vaccine (soon). That one doesn’t even need special refrigeration equipment. It could be kept in a standard refrigerator.

COVID is slowly becoming a “third world” disease. While first world countries are hoarding vaccines, having doses for populations many times their size, third world countries can’t get any because pharma companies want to sell to the first world countries first. Even then, first world countries will receive them first. While rich countries recover from COVID, they will forget about the pandemic while many other countries live the absolute worst moment of the pandemic without being able to vaccinate their population.

[krazyshoppy]

देश में पहली बार बूस्टर डोज के लिए 'मिक्स' कोरोना वैक्सीन की सिफारिश, अब सरकार लेगी फैसला

देश में पहली बार बूस्टर डोज के लिए ‘मिक्स’ कोरोना वैक्सीन की सिफारिश, अब सरकार लेगी फैसला

Corbevax Booster Dose: एनटीएजीआई (NTAGI) ने ने कोविशील्ड या कोवैक्सीन की दोनों खुराक लगवा चुके लोगों को एहतियाती खुराक (बूस्टर डोज या तीसरी खुराक) के तौर पर बायोलॉजिकल ई द्वारा विकसित कॉर्बेवैक्स (Corbevax) टीका देने की सिफारिश की है. कॉर्बेवैक्स कोविड-19 के लिए भारत का पहला स्वदेशी रूप से विकसित रिसेप्टर बाइंडिंग डोमेन (RBD) प्रोटीन सब-यूनिट वैक्सीन (Vaccine) है. सूत्रों के मुताबिक टीकाकरण पर…

[diurnalnews]

Government officials suggested the COVID vaccine, for children of age 5-11 years to avoid risk.

Government officials suggested the COVID vaccine, for children of age 5-11 years to avoid risk.

Government officials are suggesting to use Biological E’s Corbevax COVID-19 vaccine for children of age 5-11 years. Government officials on Thursday an expert committee of the Central Drug Authority of India suggests that Biological E’s COVID19 vaccine Corbevax be allotted as an emergency permit to children of age 5 to 11 years, subject to certain terms and conditions. “The Subject Expert…

[medhahospital]

#Covid vaccination drive resumes in Ghaziabad after arrival of 30,700 doses Data from Ghaziabad health department shows that only 817,939 of 2,487,074 beneficiaries – or 32.88% – have received their precautionary dose Nearly 23 days after the entire stock of Covid-19 vaccine in Ghaziabad district ran dry, the health department has received about 30,700 doses of Covishield vaccine on Tuesday night. With the arrival of the fresh stock, government vaccination centres once again started functioning on Wednesday. According to officials, the district’s stock of Covid vaccine got exhausted on December 26, and they sent a communication to the state health department requesting Covishield, Covaxin and Corbevax. “We have received about 30,700 doses of Covishield and have started the vaccination process on Wednesday. Different community health centres, primary health centres and two district hospitals have started the vaccination process. Citizens who require Covishield as a first dose, second dose or precautionary dose can get the vaccine at our centres now,” said Dr GP Mathuria, nodal officer for Covid vaccination. The health department also issued a list of 57 government vaccination centres that include urban primary health centres, community health centres in Muradnagar, Loni, Dasna and Modinagar besides the two district hospitals of MMG District Hospital and Sanjay Nagar Combined District Hospital. According to official data, Ghaziabad district had a target of vaccinating 2,844,305 beneficiaries since the Covid-19 vaccination programme started on January 16, 2021. The district surpassed this target by vaccinating 3,008,932 people with both doses (first and second dose) till January 6, the data shows. However, the slow rate of administering precautionary dose and second dose to senior citizens in the 60+ years age group has raised concerns amid reports of a new Covid-19 strain spreading in China and other countries. Data from Ghaziabad health department shows that only 817,939 of 2,487,074 beneficiaries – or 32.88% – have received their precautionary dose. Of a target of administering two doses to 361,791 beneficiaries in the 60+ age group, only 298,653 (at Ghaziabad, India) https://www.instagram.com/p/Cnn-0yIhN_V/?igshid=NGJjMDIxMWI=

[kyriolex]

Pfizer might have been the “first” COVID-19 vaccine, but Corbevax may very well be the one that will save us, because it will likely be the one going in arms around the globe.

A new COVID-19 vaccine, developed by researchers from the Texas Children’s Hospital and Baylor College of Medicine, is being offered patent-free to vaccine manufacturers across the world. Human trials have shown the vaccine to be safe and effective, with India already authorizing its use as production ramps up to over 100 million doses per month. The vaccine has been named Corbevax and it is based on a traditional protein-based technology that has been safely used for decades. Like other COVID-19 vaccines, Corbevax focuses on the coronavirus spike protein, but instead of using mRNA to direct our cells to produce those spike proteins internally it delivers lab-grown spike proteins to the body. The researchers took the gene that codes for the spike protein and engineered yeast to produce it. These proteins are collected, purified, and combined with an adjuvant to enhance immune responses. This exact method has been used to produce the hepatitis B vaccine for years. “Protein-based vaccines have been widely used to prevent many other diseases, have proven safety records, and use economies of scale to achieve low-cost scalability across the world,” says Maria Elena Bottazzi, one of the lead researchers on the project.

[nayesubah]

बिहार ��ें 12 से 15 वर्ष के बच्चों का वैक्सीनेशन ट्रायल हुआ शुरू

बिहार में 12 से 15 वर्ष के बच्चों का वैक्सीनेशन ट्रायल हुआ शुरू

Bihar: बिहार सरकार ने बच्चों के वैक्सीनेशन का प्लेटफार्म तैयार कर लिया है वैक्सीनेशन का आदेश मिलते ही 15 से 18 साल तक के बच्चों की तरह 12 साल तक के बच्चों का वैक्सीनेशन भी शुरू हो जाएगा, बिहार सरकार को केंद्र सरकार की हरी झंडी मिलने का इंतजार है आदेश मिलते हैं वैक्सीनेशन शुरू हो जाएगा। स्वास्थ्य विभाग की तैयारी के साथ स्कूलों से डेटा तैयार किया जा रहा है प्राइवेट स्कूल एसोसिएशन बच्चों का डेटा…

[bolcseszgoblin]

Okay folks. Hands up, who heard about the affordable and easy to produce, easy to ship vaccine, CORBEVAX, that is now in productionin India, after they finished the trials there in december?

No one?

It was created by Texas Children’s Hospital's Center for Vaccine Development and Baylor College of Medicine, who has been working on affordable vaccines for developing countries before. The team was led by Dr. Peter Hotez and Dr. Maria Elena Bottazzi.

It's traditional protein based technology, so it's easy to produce, with lower level of technology, it'scheap, and it does not need special refrigeration to ship. Most countries have the means to produce it, and India pledged to create billions of it, after they created the amount they need for themselves.

And they released it FREE. "As a gift to the world" It's open source, and patent-free.

Do you know who financed it? No. Not the government.

"If we had a fraction of the help that Moderna or Pfizer got from the U.S. government, or the G7 countries, in my opinion, the world could have been vaccinated by now, and we'd never be having a discussion about the Omicron variant," said Hotaz.

It was financed by random Texan people and companies, and it only took 7 million $.

The biggest contributor was Tito's Vodka with 1 million $.

Somehow the sources you will find is all Texas based papers or Indian papers. I wonder why.

“The hard part for me was we had to raise money for this, because at the time, operation WARP speed couldn’t care less about a simple durable vaccine for low and middle income countries." explained dr Hotaz

[gmartinezmolina]

RG @biotecnofarucv #Repost @uninoticias ... “Nuestra vacuna pertenece al mundo”, dice en entrevista con @aquiyahorashow la doctora hondureña María Elena Bottazzi. Fue justamente esto lo que le valió ser nominada al Premio Nobel de La Paz por desarrollar una vacuna contra el covid-19 que se ha convertido en una esperanza para países más pobres. Corbevax es una vacuna que, a diferencia de las producidas por las grandes farmacéuticas, no tiene patente y podrá ser fabricada a bajo costo en cualquier país. La doctora en microbiología del Texas Children's Hospital lleva más de una década estudiando los distintos tipos de coronavirus. El camino para desarrollar esta vacuna no fue fácil. Junto a su equipo salieron a conseguir recursos fuera de Estados Unidos para el proyecto y lo lograron. “Es un pequeño regalo que queremos hacer al mundo”, dice la doctora sobre renunciar a las ganancias para que la vacuna llegue a más personas. 👆Mira su entrevista completa en el link de nuestra biografía. #Corbevax #vacunacovid19 #honduras #texas #nobel #premionobel #nobeldelapaz Por favor Síguenos en: @biosaber.pcr @diplomadocalidadmicrob @menciondemicrobiologiaaplicada #variantedelta #ómicron #COVID-19 #vacunas #salud #sputnikv #Sinopharm #Pfizer #farmacéutico #bioanalistas #bioquímica #biotecnología #biotecnologia #microbiologia #micribiología #virtual #emprendimiento #citometriadeflujo #flowcytometry #PCR #electroforesis #felizlunes✌ https://www.instagram.com/p/CZstKFeuwi0/?utm_medium=tumblr

[astratv]

Εμβόλιο: Επιστήμονες που εφηύραν το Corbevax προτάθηκαν για το Νόμπελ Ειρήνης – Το προσέφεραν χωρίς πατέντα

Εμβόλιο: Επιστήμονες που εφηύραν το Corbevax προτάθηκαν για το Νόμπελ Ειρήνης – Το προσέφεραν χωρίς πατέντα

Δύο επιστήμονες ανέπτυξαν το Corbevax, το εμβόλιο κατά του κοροναϊού με το χαμηλό κόστος και την υψηλή αποτελεσματικότητα και το προσέφεραν στην ανθρωπότητα χωρίς δίπλωμα ευρεσιτεχνίας Δύο επιστήμονες ρίχτηκαν στη μάχη κατά του κοροναϊού με σκοπό να φτιάξουν ένα εμβόλιο προσβάσιμο σε όλους. Και τα κατάφεραν. Έτσι τώρα η Maria Elena Bottazzi, καθηγήτρια στο Baylor College of Medicine του…

[krazyshoppy]

एमपी में कोरोना रोधी टीकाकरण ने पकड़ी रफ्तार, 12-14 साल के बच्चों को इस तारीख से मिलेगी वैक्सीन

एमपी में कोरोना रोधी टीकाकरण ने पकड़ी रफ्तार, 12-14 साल के बच्चों को इस तारीख से मिलेगी वैक्सीन

Madhya Pradesh: राष्ट्रीय स्वास्थ्य मिशन (NHM) मध्यप्रदेश के संचालक टीकाकरण डॉ. संतोष शुक्ला ने मंगलवार को कहा कि, “प्रदेश में 12 से 14 साल की उम्र के किशोरों को कोविड-19 रोधी टीकाकरण 22 मार्च के बाद शुरू होगा.” इसके अलावा उन्होंने कहा कि, “प्रदेश के 60 साल से अधिक उम्र के सभी लोगों को 16 मार्च से कोविड-19 रोधी टीके की एहतियाती खुराक (बूस्टर डोज) लगाई जाएगी.” शुक्ला ने यहां एक बयान जारी कर कहा…